Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Gains from Sales and Divestitures (2023 - 2025)

Updated

Grace Therapeutics (GRCE) reported Gains from Sales and Divestitures of -$2,000 for fiscal Q4 2025 (quarter ended Mar 31, 2025), compared with $33,000 a year earlier.

Analysis

Grace Therapeutics (GRCE) Gains from Sales and Divestitures (2023 - 2025) Analysis & Trends

Dating back to fiscal Q4 2023, Grace Therapeutics' Gains from Sales and Divestitures record includes 6 quarters.

  • By fiscal year, Gains from Sales and Divestitures came in at $59,000 in FY2024 and -$39,000 in FY2023.
  • The fiscal Q4 2025 figure ranks as the lowest quarterly Gains from Sales and Divestitures since fiscal Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn
10 Grace Therapeutics 35.10 Mn -35.61 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 -2,000.00
Mar 31, 2024 33,000.00
Dec 31, 2023 1,000.00
Sep 30, 2023 38,000.00
Jun 30, 2023 -13,000.00
Mar 31, 2023 -39,000.00
API Access

Grace Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=GRCE&period=max&api_key=YOUR_API_KEY